REDISCOVER WHAT S1P THERAPY CAN MEAN FOR YOUR MULTIPLE SCLEROSIS PATIENTS
An S1P Optimized to Target With Selectivity ZEPOSIA blocks the capacity of lymphocytes to egress from lymph nodes, reducing the…
Early Intensive MS Treatment Yields Better Outcomes Than Escalation Approach
September 23, 2020 Matt Hoffman Early intensive treatment was more effective in controlling disability progression over time compared with an…
Stuart Schlossman
More on the FDA Approval of Kesimpta, B-cell Targeting Therapy for Relapsing MS
The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Kesimpta (ofatumumab) as a self-administered treatment for adults with relapsing forms of multiple sclerosis (MS),…
Stuart Schlossman
New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis
* 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease…
Stuart Schlossman
PRESS RELEASE: Genentech Expands Its Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus (ocrelizumab)
September 8, 2020 Phase III clinical trial program initiated for investigational medicine fenebrutinib, designed to be a highly selective and…
Stuart Schlossman
Mavenclad Lowers MS Relapse Rates, Study Comparing …
Click HERE to Subscribe for the MS Beacon Newsletter Mavenclad (cladribine) appears to be better at lowering relapse rates during the…
Stuart Schlossman
LEMTRADA: Who is the Right Patient for this Multiple Sclerosis Drug?
vlog produced by Aaron Boster, MD Click HERE to Subscribe for the MS Beacon Newsletter Information Shared by: MSViewsandNews, Visit our…
Stuart Schlossman
Launching a new MS drug responsibly, during Covid-19
Click HERE to Subscribe for the MS Beacon Newsletter As a company, Novartis had to ask themselves what launching a…
Stuart Schlossman
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Click HERE to Subscribe for the MS Beacon Newsletter East Hanover, August 20, 2020 — Novartis today announced that…
Stuart Schlossman
Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera®
Click HERE to Subscribe for the MS Beacon Newsletter HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) today announced the launch of the…
Stuart Schlossman
